MHRA-100579-PIP01-22-M01 (update)

Key Facts

Active Substance
Active Substance:
  • Maribavir
Invented Name
  • Livtencity
  • Livtencity
PIP Number MHRA-100579-PIP01-22-M01 (update)
Pharmaceutical form(s)
  • Film-coated tablet
  • Powder for oral suspension
  • Tablet for oral suspension
Therapeutic area
Therapeutic area:
  • Infectious diseases
Conditions / Indications
Conditions / Indications:
  • Treatment of cytomegalovius (CMV) infection
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
  • Takeda Pharmaceuticals International AG Ireland Branch
  • Country Ireland
  • Tel 03333000181
  • Email medinfoemea@takeda.com
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Maribavir.pdf
Published Date 02/02/2023